Out of Shortage, Into Controversy: The Fight Over GLP-1 Compounding
Pharmacy Times
JULY 18, 2025
Rumore, PharmD, Esq, MS, LLM, FAPhA Key Takeaways The removal of tirzepatide and semaglutide from the FDA's shortage list impacts 503A compounders, requiring adherence to complex legal and regulatory frameworks. The definition of "essentially a copy" is pivotal, influencing compounding practices and legal interpretations.
Let's personalize your content